Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.

被引：0
|
作者：
Babiker, Hani M.
Macarulla, Teresa
Philip, Agop Philip
Becerra, Carlos Roberto
Dragovich, Tomislav
Picozzi, Vincent J.
机构：
[1] Mayo Clin Florida, Jacksonville, FL USA
[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Karmanos Canc Inst, Detroit, MI USA
[4] Hoag Family Canc Inst, Newport Beach, CA USA
[5] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[6] Virginia Mason Hosp & Med Ctr, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4199
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [42] PANOVA: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma-Updated efficacy results.
    Benavides, Manuel
    Guillen, Carmen
    Rivera, Fernando
    Gallego, Javier
    Lopez-Martin, Jose A.
    Kung, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] PANOVA-2: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma - Updated efficacy results
    Manuel, Benavides
    Carmen, Guillen-Ponce
    Fernando, Rivera
    Javier, Gallego
    Jose, Lopez-Martin
    Marc, Kueng
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer
    Ko, A. H.
    Cubillo, A.
    Kundranda, M.
    Zafar, S. F.
    Meiri, E.
    Bendell, J.
    Alguel, H.
    Herrero, F. Rivera
    Ahn, E.
    Watkins, D.
    Pelzer, U.
    Charu, V.
    Downing, W.
    Wang, B.
    Kuesters, G.
    Pipas, J. M.
    Santillana, S. L.
    Askoxylakis, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
    Kundranda, M.
    Gracian, A. C.
    Zafar, S. F.
    Meiri, E.
    Bendell, J.
    Alguel, H.
    Rivera, F.
    Ahn, E. R.
    Watkins, D.
    Pelzer, U.
    Charu, V
    Zalutskaya, A.
    Kuesters, G.
    Pipas, J. M.
    Santillana, S.
    Askoxylakis, V
    Ko, A. H.
    ANNALS OF ONCOLOGY, 2020, 31 (01) : 79 - 87
  • [46] Phase Ib/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
    Acoba, Jared David
    Rock, Amy
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [47] Phase I study of chemoradiation therapy (nab-paclitaxel/Gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC).
    Sueyoshi, Hironari
    Ioka, Tatsuya
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Final report: A phase I trial of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
    Soares, Heloisa P.
    Al-Toubah, Taymeyah E.
    Kim, Richard D.
    Kim, Jongphil
    Lewis, Neron K.
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
    Soares, Heloisa P.
    Springett, Gregory M.
    Kim, Richard D.
    Williams-Elson, Irene
    Miller, Kara
    Kothari, Nishi
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [50] Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
    Petrioli, Roberto
    Torre, Pamela
    Pesola, Guido
    Paganini, Giovanni
    Paolelli, Loretta
    Miano, Salvatora Tindara
    Martellucci, Ignazio
    Francini, Guido
    Francini, Edoardo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 647 - 651
12345